Puma Biotechnology, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 05, 2021 at 04:17 pm EDT
Share
Puma Biotechnology, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 53.4 million compared to USD 70.6 million a year ago. Operating loss was USD 16.6 million compared to operating Income of USD 7.1 million a year ago. Net loss was USD 5.1 million compared to net income of USD 3.4 million a year ago. Basic loss per share from continuing operations was USD 0.13 compared to basic earnings per share from continuing operations of USD 0.09 a year ago. Diluted loss per share from continuing operations was USD 0.13 compared to diluted earnings per share from continuing operations of USD 0.08 a year ago. For the half year, total revenue was USD 151.6 million compared to USD 121.8 million a year ago. Operating income was USD 3.5 million compared to operating loss of USD 7.1 million a year ago. Net income was USD 11.3 million compared to net loss of USD 13.5 million a year ago. Basic earnings per share from continuing operations was USD 0.28 compared to basic loss per share from continuing operations of USD 0.34 a year ago.
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.
PUMA BIOTECHNOLOGY, INC. 
